-
H.C. Wainwright Reiterates Buy Rating on ADC Therapeutics (ADCT)
-
ADC Therapeutics SA (ADCT) Tops Q2 EPS by 14c
-
ADC Therapeutics (ADCT) PT Lowered to $5 at RBC Capital
-
ADC Therapeutics SA (ADCT) Announces Updated Data from ZYNLONTA Investigator-Initiated Trial R/R Marginal Zone Lymphoma
-
ADC Therapeutics (ADCT) PT Raised to $10 at Guggenheim
-
ADC Therapeutics SA (ADCT) Prices $100M Share Offering at $3.53/sh
-
ADC Therapeutics SA (ADCT) Announces Updated Data from LOTIS-7 Clinical Trial
-
ADC Therapeutics SA (ADCT) Tops Q1 EPS by 18c
-
ADC Therapeutics SA (ADCT) Announces Presentation of LOTIS-7 Clinical Trial Data
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
ADC Therapeutics (ADCT) PT Lowered to $7 at Guggenheim
-
RBC Capital on ADC Therapeutics (ADCT): 'A Critical Year Ahead for Zynlonta Expansion De-Risking'
-
ADC Therapeutics SA (ADCT) Tops Q4 EPS by 18c
-
ADC Therapeutics (ADCT) PT Raised to $8 at Stephens
-
H.C. Wainwright Reiterates Buy Rating on ADC Therapeutics (ADCT)
-
ADC Therapeutics (ADCT) Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cel
-
ADC Therapeutics SA (ADCT) Tops Q3 EPS by 10c
-
ADC Therapeutics SA (ADCT) Files $300M Mixed Shelf
-
ADC Therapeutics (ADCT) to Join Russell 2000 and Russell 3000 Indexes

